S3-Leitlinie Prostatakarzinom - AWMF

9. Literatur
171. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten
A, Sternberg C, Mattelaer J, Lopez TJ, Pfeffer JR, Lino CC, Zurlo A, Pierart M. Long-term
results with immediate androgen suppression and external irradiation in patients with
locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet
2002;360(9327):103-6. http://www.ncbi.nlm.nih.gov/pubmed/12126818
172. Bolla M, Van TG, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg
C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, van der KT, Collette L. External irradiation with
or without long-term androgen suppression for prostate cancer with high metastatic risk:
10-year results of an EORTC randomised study. Lancet Oncol 2010;11(11):1066-73.
http://www.ncbi.nlm.nih.gov/pubmed/20933466
173. Lawton CA, Winter K, Grignon D, Pilepich MV. Androgen suppression plus radiation versus
radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the
prostate: updated results based on national prospective randomized trial Radiation Therapy
Oncology Group 85-31. Journal of clinical oncology : official journal of the American Society
of Clinical Oncology 2005;23(4):800-7. http://www.ncbi.nlm.nih.gov/pubmed/15681524
174. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO,
Grignon D. Androgen suppression adjuvant to definitive radiotherapy in prostate
carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys
2005;61(5):1285-90. http://www.ncbi.nlm.nih.gov/pubmed/15817329
175. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and
radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008;299(3):289-
95. http://www.ncbi.nlm.nih.gov/pubmed/18212313
176. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA,
Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology
group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in
locally advanced prostate cancer. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2008;26(15):2497-504.
http://www.ncbi.nlm.nih.gov/pubmed/18413638
177. Pommier P, Chabaud S, Lagrange JL, Richaud P, Lesaunier F, Le PE, Wagner JP, Hay MH,
Beckendorf V, Suchaud JP, Pabot du Chatelard PM, Bernier V, Voirin N, Perol D, Carrie C. Is
there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results
of GETUG-01. J Clin Oncol 2007;25(34):5366-73.
http://www.ncbi.nlm.nih.gov/pubmed/18048817
178. Lawton CA, DeSilvio M, Roach M, III, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S,
Valicenti R, Hahn S, Thomas CR, Jr. An update of the phase III trial comparing whole pelvic
to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression:
updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation
interactions. Int J Radiat Oncol Biol Phys 2007;69(3):646-55.
http://www.ncbi.nlm.nih.gov/pubmed/17531401
179. Morikawa LK, Roach M, III. Pelvic nodal radiotherapy in patients with unfavorable
intermediate and high-risk prostate cancer: evidence, rationale, and future directions. Int J
Radiat Oncol Biol Phys 2011;80(1):6-16. http://www.ncbi.nlm.nih.gov/pubmed/21481721
180. Gemeinsamer Bundesausschuss (G-BA). Protonentherapie Indikation: Prostatakarzinom.
Abschlussbericht des Unterausschusses „Methodenbewertung" des Gemeinsamen
Bundesausschusses (3. Update-Recherche). 2008 [cited: 2011 Jul 05]. Available from:
http://www.g-ba.de/downloads/40-268-739/2008-06-19_Abschluss_Protonen-
Prostatakarzinom.pdf
181. Ollendorf DA, Hayes J, McMahon P, Pearson SD, Kuba M, Tramontano A. Brachytherapy &
Proton Beam Therapy for treatment of clinically-localized, low-risk prostate cancer. Institute
for Clinical and Economic Review. Final Appraisal Document. 2008 Available from:
http://www.icer-review.org/index.php/Download-document/43-Executive-Summary-
© Leitlinienprogramm Onkologie | S3-Leitlinie Prostatakarzinom | Version 2.0, 1. Aktualisierung 2011